CorMedix
CRMD
74 hedge funds and large institutions have $49.4M invested in CorMedix in 2022 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 23 increasing their positions, 20 reducing their positions, and 24 closing their positions.
15% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 20
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
3.32% less ownership
Funds ownership: 35.08% → 31.77% (-3.3%)
13% less funds holding
Funds holding: 85 → 74 (-11)
33% less capital invested
Capital invested by funds: $73.4M → $49.4M (-$24M)
33% less call options, than puts
Call options by funds: $362K | Put options by funds: $542K
38% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 24
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Barclays
London,
United Kingdom
|
+$2.76M |
| 2 |
Millennium Management
New York
|
+$2.47M |
| 3 |
Nomura Holdings
Tokyo,
Japan
|
+$2.04M |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$1.05M |
| 5 |
E
Ergoteles
New York
|
+$681K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$6.63M |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$2.8M |
| 3 |
State Street
Boston,
Massachusetts
|
-$1.83M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$1.23M |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$941K |
CRMD Hedge Fund Activity: Q2 2022 in Review
74 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in CorMedix (CRMD) for Q2 2022, worth a combined $49.4M — down 33% from $73.4M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of CRMD and 15 opened new positions — a net loss of 9 holders — while 20 trimmed existing stakes and 23 added.
The largest buyer was Barclays, adding an estimated $2.76M. The largest seller was BlackRock, cutting an estimated $6.63M.
- 74 institutional investors held CorMedix (CRMD) as of Q2 2022, down from 85 in Q1 2022.
- Funds reported $49.4M of CorMedix stock for Q2 2022, down 33% quarter-over-quarter.
- 15 funds opened new CorMedix positions in Q2 2022 and 24 closed out, a net change of -9 holders.
- The largest CorMedix buyer in Q2 2022 was Barclays, an estimated $2.76M added.
- The largest CorMedix seller in Q2 2022 was BlackRock, an estimated $6.63M sold.
Based on aggregated 13F filings for Q2 2022.